RVL Pharmaceuticals Statistics
Total Valuation
RVL Pharmaceuticals has a market cap or net worth of 111. The enterprise value is 38.99 million.
| Market Cap | 111 |
| Enterprise Value | 38.99M |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RVL Pharmaceuticals has 111.41 million shares outstanding.
| Shares Outstanding | 111.41M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 2.76% |
| Owned by Institutions (%) | n/a |
| Float | 96.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.00 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.57 |
| EV / Sales | 1.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.82 |
Financial Position
The company has a current ratio of 0.38, with a Debt / Equity ratio of 356.16.
| Current Ratio | 0.38 |
| Quick Ratio | 0.31 |
| Debt / Equity | 356.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.22 |
| Interest Coverage | -33.53 |
Financial Efficiency
Return on equity (ROE) is -182.44% and return on invested capital (ROIC) is -28.03%.
| Return on Equity (ROE) | -182.44% |
| Return on Assets (ROA) | -23.65% |
| Return on Capital (ROIC) | -28.03% |
| Revenue Per Employee | 295,352 |
| Profits Per Employee | -546,128 |
| Employee Count | 125 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 6.93 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.90% in the last 52 weeks. The beta is 22.11, so RVL Pharmaceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 22.11 |
| 52-Week Price Change | -99.90% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 45.31 |
| Average Volume (20 Days) | 51,724 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.08 |
Income Statement
In the last 12 months, RVL Pharmaceuticals had revenue of 36.92 million and -68.27 million in losses. Loss per share was -0.70.
| Revenue | 36.92M |
| Gross Profit | 30.39M |
| Operating Income | -39.77M |
| Pretax Income | -68.54M |
| Net Income | -68.27M |
| EBITDA | -39.39M |
| EBIT | -39.77M |
| Loss Per Share | -0.70 |
Balance Sheet
The company has 19.16 million in cash and 58.15 million in debt, giving a net cash position of -38.99 million or -0.35 per share.
| Cash & Cash Equivalents | 19.16M |
| Total Debt | 58.15M |
| Net Cash | -38.99M |
| Net Cash Per Share | -0.35 |
| Equity (Book Value) | 16.33M |
| Book Value Per Share | 0.16 |
| Working Capital | -42.64M |
Cash Flow
In the last 12 months, operating cash flow was -44.41 million and capital expenditures -3.08 million, giving a free cash flow of -47.49 million.
| Operating Cash Flow | -44.41M |
| Capital Expenditures | -3.08M |
| Free Cash Flow | -47.49M |
| FCF Per Share | -0.43 |
Margins
Gross margin is 82.31%, with operating and profit margins of -107.73% and -184.91%.
| Gross Margin | 82.31% |
| Operating Margin | -107.73% |
| Pretax Margin | -185.66% |
| Profit Margin | -184.91% |
| EBITDA Margin | -106.69% |
| EBIT Margin | -107.73% |
| FCF Margin | -128.62% |
Dividends & Yields
RVL Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.65% |
| Shareholder Yield | -25.65% |
| Earnings Yield | -69,871,200.00% |
| FCF Yield | -42,623,361.10% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RVL Pharmaceuticals has an Altman Z-Score of -10.42. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.42 |
| Piotroski F-Score | n/a |